LIVIVO - Search results -

Search results

Result 1 - 10 of total 30

Search options

Article ; Online: Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.

Avenarius, Matthew R / Huang, Ying / Kittai, Adam S / Bhat, Seema A / Rogers, Kerry A / Grever, Michael R / Woyach, Jennifer A / Miller, Cecelia R

Leukemia

2024 Volume 38, Issue 3, Page(s) 676–678

MeSH term(s)	Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Karyotyping ; Karyotype
Language	English
Publishing date	2024-02-19
Publishing country	England
Document type	Letter
ZDB-ID	807030-1
ISSN	1476-5551 ; 0887-6924
ISSN (online)	1476-5551
ISSN	0887-6924
DOI	10.1038/s41375-024-02177-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2295: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Culture and Harvest of CpG-Stimulated Peripheral Blood or Bone Marrow in Chronic Lymphocytic Leukemia.

Miller, Cecelia R / Heerema, Nyla A

Methods in molecular biology (Clifton, N.J.)

2018 Volume 1881, Page(s) 27–34

Abstract: Chromosome analysis of chronic lymphocytic leukemia (CLL) is an important clinical tool for evaluating prognosis and disease progression. Visualizing chromosomes microscopically using traditional cytogenetic techniques requires dividing cells to be ... ...

Abstract	Chromosome analysis of chronic lymphocytic leukemia (CLL) is an important clinical tool for evaluating prognosis and disease progression. Visualizing chromosomes microscopically using traditional cytogenetic techniques requires dividing cells to be arrested during metaphase. The major challenge for performing this analysis on CLL samples is stimulating the cells to divide in culture. Stimulation of CLL cells with CpG oligodeoxynucleotides has improved our ability to perform chromosome analysis for this leukemia. This protocol should help the reader successfully culture CLL samples for clinical chromosome analysis.
MeSH term(s)	B-Lymphocytes/drug effects ; Bone Marrow Cells/drug effects ; Humans ; Karyotyping/instrumentation ; Karyotyping/methods ; Leukemia, Lymphocytic, Chronic, B-Cell/blood ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Metaphase/drug effects ; Mitogens/pharmacology ; Oligodeoxyribonucleotides/pharmacology ; Primary Cell Culture/instrumentation ; Primary Cell Culture/methods ; Specimen Handling/instrumentation ; Specimen Handling/methods ; Tumor Cells, Cultured
Chemical Substances	CPG-oligonucleotide ; GNKG168 ; Mitogens ; Oligodeoxyribonucleotides
Language	English
Publishing date	2018-10-22
Publishing country	United States
Document type	Journal Article
ISSN	1940-6029
ISSN (online)	1940-6029
DOI	10.1007/978-1-4939-8876-1_3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization.

Teierle, Samantha M / Huang, Ying / Kittai, Adam S / Bhat, Seema A / Grever, Michael / Rogers, Kerry A / Zhao, Weiqiang / Jones, Daniel / Byrd, John C / Avenarius, Matthew R / Heerema, Nyla A / Woyach, Jennifer A / Miller, Cecelia R

Blood advances

2023 Volume 7, Issue 23, Page(s) 7239–7242

MeSH term(s)	Humans ; In Situ Hybridization, Fluorescence ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Chromosome Deletion ; Gene Deletion ; Cyclin-Dependent Kinase Inhibitor p16/genetics
Chemical Substances	CDKN2A protein, human ; Cyclin-Dependent Kinase Inhibitor p16
Language	English
Publishing date	2023-10-18
Publishing country	United States
Document type	Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2023010753
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes.

Hyak, Jonathan M / Huang, Ying / Rogers, Kerry A / Bhat, Seema A / Grever, Michael R / Byrd, John C / Kittai, Adam S / Jones, Dan / Miller, Cecelia R / Woyach, Jennifer A

Blood advances

2022 Volume 6, Issue 17, Page(s) 5124–5127

MeSH term(s)	Agammaglobulinaemia Tyrosine Kinase ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Proto-Oncogene Proteins c-bcl-2 ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use
Chemical Substances	BCL2 protein, human ; Proto-Oncogene Proteins c-bcl-2 ; Pyrimidines ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2)
Language	English
Publishing date	2022-07-09
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2022007708
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results.

Avenarius, Matthew R / Huang, Ying / Hyak, Jonathan / Byrd, John C / Bhat, Seema A / Grever, Michael / Kittai, Adam S / Rogers, Kerry A / Jones, Dan / Zhao, Weiqiang / Heerema, Nyla A / Abruzzo, Lynne V / Woyach, Jennifer / Miller, Cecelia R

Hematological oncology

2023 Volume 41, Issue 4, Page(s) 771–775

Abstract: Fluorescence in situ hybridization (FISH) to detect the recurrent cytogenetics abnormalities deletion 13q, trisomy 12, deletion 11q, and deletion 17p is important for prognostication in chronic lymphocytic leukemia (CLL). A subset of patients are ... ...

Abstract	Fluorescence in situ hybridization (FISH) to detect the recurrent cytogenetics abnormalities deletion 13q, trisomy 12, deletion 11q, and deletion 17p is important for prognostication in chronic lymphocytic leukemia (CLL). A subset of patients are negative for each of these abnormalities (normal 12/13/11/17 FISH), and outcomes are heterogenous within this group. To elucidate variables important for prognostication in this subgroup we conducted a retrospective analysis of 280 treatment-naïve CLL patients with normal standard CLL FISH results. In a multivariable model, advanced Rai stage (p = 0.04, hazard ratio [HR] 1.24 (95% confidence interval [CI] 1.01-1.53)), unmutated immunoglobulin heavy chain gene (IGHV) (p < 0.0001, HR 5.59 (95% CI 3.63-8.62)) and IGH rearrangement by FISH (p = 0.02, HR 2.56 (95% CI 1.20-5.48)) were significantly associated with shorter time to first treatment. In a multivariable model for overall survival, increasing age at 5-year increments (p < 0.0001, HR 1.55 (95% CI 1.25-1.93)), unmutated IGHV (p = 0.01, HR 5.28 (95% CI 1.52-18.35)) and gain of REL (p = 0.01, HR 4.08 (5% CI 1.45-11.49)) were significantly associated with shorter survival. Our study identifies variables important for refining prognosis for CLL patients with normal standard CLL FISH results.
MeSH term(s)	Humans ; Child, Preschool ; In Situ Hybridization, Fluorescence/methods ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Retrospective Studies ; Chromosome Aberrations ; Prognosis
Language	English
Publishing date	2023-04-03
Publishing country	England
Document type	Letter
ZDB-ID	604884-5
ISSN	1099-1069 ; 0278-0232
ISSN (online)	1099-1069
ISSN	0278-0232
DOI	10.1002/hon.3134
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1816: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.

Kittai, Adam S / Huang, Ying / Beckwith, Kyle A / Bhat, Seema A / Bond, David A / Byrd, John C / Goldstein, Daniel / Grever, Michael R / Miller, Cecelia / Rogers, Kerry A / Yano, Max / Woyach, Jennifer A

American journal of hematology

2022 Volume 98, Issue 1, Page(s) 56–65

Abstract: Chronic lymphocytic leukemia (CLL) transformation to aggressive lymphoma, known as Richter's Transformation (RT), has a dismal prognosis. There are limited data evaluating risk of RT in patients treated with ibrutinib. We performed a retrospective ... ...

Abstract	Chronic lymphocytic leukemia (CLL) transformation to aggressive lymphoma, known as Richter's Transformation (RT), has a dismal prognosis. There are limited data evaluating risk of RT in patients treated with ibrutinib. We performed a retrospective analysis to determine prognostic variables associated with development of RT and overall survival (OS) at progression after treatment with ibrutinib. We identified 559 patients with CLL treated with ibrutinib from 2010-2019. After a median follow-up of 44.5 months from ibrutinib start, 179 patients progressed and were included in our analysis. After a median follow-up of 20.8 months from progression, 54 out of 179 patients developed RT. Progression on treatment (hazard ratio [HR] 4.01 [1.60-10.00], p = .003), higher LDH (HR 1.80 for 2-fold increase [1.33-2.43], p = .0001), and lymphadenopathy without lymphocytosis (HR 2.88 [1.15-7.20], p = .02) were independent prognostic variables for the development of RT at progression. Progression with lymphadenopathy without lymphocytosis continued to be an independent prognostic variable of worse OS post-progression. In a subset analysis of 50 patients who obtained a PET-CT at progression, the median SUV
MeSH term(s)	Humans ; Leukemia, Lymphocytic, Chronic, B-Cell ; Positron Emission Tomography Computed Tomography ; Retrospective Studies ; Lymphocytosis ; Lymphoma, Large B-Cell, Diffuse ; Lymphadenopathy
Chemical Substances	ibrutinib (1X70OSD4VX)
Language	English
Publishing date	2022-10-20
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	196767-8
ISSN	1096-8652 ; 0361-8609
ISSN (online)	1096-8652
ISSN	0361-8609
DOI	10.1002/ajh.26755
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1251: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.

Kittai, Adam S / Bond, David / Huang, Ying / Bhat, Seema A / Blyth, Emily / Byrd, John C / Chavez, Julio C / Davids, Matthew S / Dela Cruz, Jamie P / Dowling, Mark R / Duffy, Caitlyn / Ho, Carrie / Jacobson, Caron / Jaglowski, Samantha / Jain, Nitin / Lin, Kevin H / Miller, Cecelia / McCarthy, Christine / Omer, Zulfa /

Parry, Erin / Rai, Manoj / Rogers, Kerry A / Saha, Aditi / Schachter, Levanto / Scott, Hamish / Senapati, Jayastu / Shadman, Mazyar / Siddiqi, Tanya / Stephens, Deborah M / Vanguru, Vinay / Wierda, William / Woyach, Jennifer A / Thompson, Philip A

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2024 , Page(s) JCO2400033

Abstract: Purpose: Outcomes for Richter transformation (RT) are poor with current therapies. The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for RT are not established.: Methods: We performed an international multicenter ... ...

Abstract	Purpose: Outcomes for Richter transformation (RT) are poor with current therapies. The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for RT are not established. Methods: We performed an international multicenter retrospective study of patients with RT who received CAR-T. Patient, disease, and treatment characteristics were summarized using descriptive statistics, and modeling analyses were used to determine association with progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated from the date of CAR-T infusion. Results: Sixty-nine patients were identified. The median age at CAR-T infusion was 64 years (range, 27-80). Patients had a median of four (range, 1-15) previous lines of therapy for CLL and/or RT, including previous Bruton tyrosine kinase inhibitor and/or BCL2 inhibitor therapy in 58 (84%) patients. The CAR-T product administered was axicabtagene ciloleucel in 44 patients (64%), tisagenlecleucel in 17 patients (25%), lisocabtagene maraleucel in seven patients (10%), and brexucabtagene autoleucel in one patient (1%). Eleven patients (16%) and 25 patients (37%) experienced grade ≥3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, respectively. The overall response rate was 63%, with 46% attaining a complete response (CR). After a median follow-up of 24 months, the median PFS was 4.7 months (95% CI, 2.0 to 6.9); the 2-year PFS was 29% (95% CI, 18 to 41). The median OS was 8.5 months (95% CI, 5.1 to 25.4); the 2-year OS was 38% (95% CI, 26 to 50). The median duration of response was 27.6 months (95% CI, 14.5 to not reached) for patients achieving CR. Conclusion: CAR-T demonstrates clinical efficacy for patients with RT.
Language	English
Publishing date	2024-03-29
Publishing country	United States
Document type	Journal Article
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.24.00033
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.

Woyach, Jennifer A / Perez Burbano, Gabriela / Ruppert, Amy S / Miller, Cecelia / Heerema, Nyla A / Zhao, Weiqiang / Wall, Anna / Ding, Wei / Bartlett, Nancy L / Brander, Danielle M / Barr, Paul M / Rogers, Kerry A / Parikh, Sameer A / Stephens, Deborah M / Brown, Jennifer R / Lozanski, Gerard / Blachly, James / Nattam, Sreenivasa / Larson, Richard A /

Erba, Harry / Litzow, Mark / Luger, Selina / Owen, Carolyn / Kuzma, Charles / Abramson, Jeremy S / Little, Richard F / Dinner, Shira / Stone, Richard M / Uy, Geoffrey / Stock, Wendy / Mandrekar, Sumithra J / Byrd, John C

Blood

2024 Volume 143, Issue 16, Page(s) 1616–1627

Abstract: Abstract: A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with chronic lymphocytic leukemia (CLL). The initial ...

Abstract	Abstract: A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with chronic lymphocytic leukemia (CLL). The initial results showed that ibrutinib-containing regimens had superior progression-free survival (PFS) and rituximab did not add additional benefits. Here we present an updated analysis. With a median follow-up of 55 months, the median PFS was 44 months (95% confidence interval [CI], 38-54) for BR and not yet reached in either ibrutinib-containing arm. The 48-month PFS estimates were 47%, 76%, and 76% for BR, ibrutinib, and IR, respectively. The benefit of ibrutinib regimens over chemoimmunotherapy was consistent across subgroups of patients defined by TP53 abnormalities, del(11q), complex karyotype, and immunoglobulin heavy chain variable region (IGHV). No significant interaction effects were observed between the treatment arm and del(11q), the complex karyotype, or IGHV. However, a greater difference in PFS was observed among the patients with TP53 abnormalities. There was no difference in the overall survival. Notable adverse events with ibrutinib included atrial fibrillation (afib) and hypertension. Afib was observed in 11 patients (pts) on BR (3%) and 67 pts on ibrutinib (18%). All-grade hypertension was observed in 95 pts on BR (27%) and 263 pts on ibrutinib (55%). These data show that ibrutinib regimens prolong PFS compared with BR for older patients with treatment-naïve CLL. These benefits were observed across subgroups, including high-risk groups. Strikingly, within the ibrutinib arms, there was no inferior PFS for patients with abnormalities in TP53, the highest risk feature observed in CLL. These data continue to demonstrate the efficacy of ibrutinib in treatment-naïve CLL.
MeSH term(s)	Humans ; Aged ; Rituximab/therapeutic use ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Follow-Up Studies ; Atrial Fibrillation/etiology ; Bendamustine Hydrochloride/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Hypertension/etiology ; Adenine/analogs & derivatives ; Piperidines
Chemical Substances	Rituximab (4F4X42SYQ6) ; ibrutinib (1X70OSD4VX) ; Bendamustine Hydrochloride (981Y8SX18M) ; Adenine (JAC85A2161) ; Piperidines
Language	English
Publishing date	2024-01-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.2023021959
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.

Miller, Cecelia R / Huang, Ying / Ruppert, Amy S / Labanowska, Jadwiga / Jaglowski, Samantha M / Maddocks, Kami J / Rogers, Kerry A / Bhat, Seema / Kittai, Adam S / Grever, Michael / Lapalombella, Rosa / Abruzzo, Lynne V / Heerema, Nyla A / Byrd, John C / Hertlein, Erin K / Woyach, Jennifer A

Leukemia

2021 Volume 35, Issue 11, Page(s) 3287–3290

MeSH term(s)	Adenine/analogs & derivatives ; Adenine/therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Chromosome Aberrations ; Chromosomes, Human, Pair 2/genetics ; Cohort Studies ; Female ; Follow-Up Studies ; Gene Dosage ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Middle Aged ; Piperidines/therapeutic use ; Prognosis ; Survival Rate
Chemical Substances	Piperidines ; ibrutinib (1X70OSD4VX) ; Adenine (JAC85A2161)
Language	English
Publishing date	2021-04-05
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	807030-1
ISSN	1476-5551 ; 0887-6924
ISSN (online)	1476-5551
ISSN	0887-6924
DOI	10.1038/s41375-021-01237-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2295: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing.

Avenarius, Matthew R / Miller, Cecelia R / Arnold, Michael A / Koo, Selene / Roberts, Ryan / Hobby, Martin / Grossman, Thomas / Moyer, Yvonne / Wilson, Richard K / Mardis, Elaine R / Gastier-Foster, Julie M / Pfau, Ruthann B

The Journal of molecular diagnostics : JMD

2020 Volume 22, Issue 10, Page(s) 1238–1245

Abstract: Somatic variants, primarily fusion genes and single-nucleotide variants (SNVs) or insertions/deletions (indels), are prevalent among sarcomas. In many cases, accurate diagnosis of these tumors incorporates genetic findings that may also carry prognostic ... ...

Abstract	Somatic variants, primarily fusion genes and single-nucleotide variants (SNVs) or insertions/deletions (indels), are prevalent among sarcomas. In many cases, accurate diagnosis of these tumors incorporates genetic findings that may also carry prognostic or therapeutic significance. Using the anchored multiplex PCR-based FusionPlex system, a custom RNA sequencing panel was developed that simultaneously detects fusion genes, SNVs, and indels in 112 genes found to be recurrently mutated in solid tumors. Using this assay, a retrospective analysis was conducted to identify somatic variants that may have assisted with classifying a cohort of 90 previously uncharacterized primarily pediatric sarcoma specimens. In total, somatic variants were identified in 45.5% (41/90) of the samples tested, including 22 cases with fusion genes and 19 cases with SNVs or indels. In addition, two of these findings represent novel alterations: a WHSC1L1/NCOA2 fusion and a novel in-frame deletion in the NRAS gene (NM_002524: c.174_176delAGC p.Ala59del). These sequencing results, taken in context with the available clinical data, indicate a potential change in the initial diagnosis, prognosis, or management in 27 of the 90 cases. This study presents a custom RNA sequencing assay that detects fusion genes and SNVs in tandem and has the ability to identify novel fusion partners. These features highlight the advantages associated with utilizing anchored multiplex PCR technology for the rapid and highly sensitive detection of somatic variants.
MeSH term(s)	Child ; Child, Preschool ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; Sarcoma/genetics ; Sequence Analysis, RNA
Language	English
Publishing date	2020-08-01
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2000060-1
ISSN	1943-7811 ; 1525-1578
ISSN (online)	1943-7811
ISSN	1525-1578
DOI	10.1016/j.jmoldx.2020.07.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito